姓 名: |
杜璟 |
工作单位: |
附属人民医院 |
|
职 称: |
主治医师 |
职 务: |
||
办公电话: |
13616718023 |
邮 箱: |
dujing1@hmc.edu.cn |
|
学科专业: |
基础医学,公共卫生与预防医学 |
|||
研究方向: |
铁死亡机制与运用研究。 |
浙江省人民医院检验中心主任助理。
2013/09-2016/06,温州医科大学,临床检验诊断学,硕士。
2016/08-至今,浙江省人民医院,检验中心
近五年,以第一或通讯作者发表SCI论著30篇,其中热点论文1篇,高被引论文4篇,IF>10分论文3篇,中科院TOP期刊12篇,总影响因子200余分。参与获得浙江省科学技术进步奖“二等奖”两项;授权专利六项,荣获“中国专利优秀奖”。
担任浙江省医学会检验医师分会青年委员,浙江省医学会精准医学分会青年委员,浙江省抗癌协会肿瘤标志物专委会青年委员。多次荣获浙江省人民医院“优秀教学秘书”及杭州医学院“优秀带教老师”。
担任浙江省医学会检验医师分会青年委员,浙江省医学会精准医学分会青年委员,浙江省抗癌协会肿瘤标志物专委会青年委员。
主持国家自然科学基金1项、浙江省自然科学基金2项、卫生厅及医院课题4项,协助团队成员获得各类课题资助十余项。入选浙江省卫生高层次人才“医坛新秀”培养对象。多次荣获杭州医学院及浙江省人民医院“优秀科研奖”荣誉称号。
主持的省级以上课题:
(1) 国家自然科学基金,82102938,铁硫蛋白CISD2通过代谢重编程调控Keap1-NRF2-FTH信号轴介导RAS突变肿瘤细胞铁死亡的机制研究,2022/01-2024/12,30万元,在研,主持。
(2) 浙江省基础公益项目,LBY23H080005,小分子抑制剂Thiotert通过TRX-NCOA4-FTH通路调控MDS细胞铁死亡,2023/01-2025/12,10万元,在研,主持。
(3) 浙江省基础公益项目,GF19H080014,靶向CISD2蛋白下调p62-Keap1-NRF2通路诱导急性髓系白血病铁死亡的应用研究,2019/01-2021/12,10万元,已结题,主持。
近五年,以第一或通讯作者发表SCI论著30篇,其中热点论文1篇,高被引论文4篇,IF>10分论文3篇,中科院TOP期刊12篇,总影响因子200余分。
以第一作者或通讯作者发表的代表性文章:
1. Du J, Wang T, Li Y, et al. DHA inhibits proliferation and induces ferroptosis of leukemia cells through autophagy dependent degradation of ferritin. Free Radic Biol Med. 2019;131:356-369. (highly cited paper, number of citations: 247)
2. Du J, Zhou Y, Li Y, et al. Identification of Frataxin as a regulator of ferroptosis. Redox Biol. 2020;32:101483. (highly cited paper, number of citations: 105)
3. Ren X, Li Y, Zhou Y, et al. Overcoming the compensatory elevation of NRF2 renders hepatocellular carcinoma cells more vulnerable to disulfiram/copper-induced ferroptosis. Redox Biol. 2021;46:102122. (hot paper, number of citations: 97)
4. Li Y, Wang X, Huang Z, et al. CISD3 inhibition drives cystine-deprivation induced ferroptosis. Cell Death Dis. 2021;12(9):839. (number of citations: 39)
5. Du J, Wang X, Li Y, et al. DHA exhibits synergistic therapeutic efficacy with cisplatin to induce ferroptosis in pancreatic ductal adenocarcinoma via modulation of iron metabolism. Cell Death Dis. 2021;12(7):705. (highly cited paper, number of citations: 68)
6. Li Y, Xia J, Shao F, et al. Sorafenib induces mitochondrial dysfunction and exhibits synergistic effect with cysteine depletion by promoting HCC cells ferroptosis. Biochem Biophys Res Commun. 2021;534:877-884. (highly cited paper, number of citations: 59)
7. Hu W, Zhou C, Jing Q, Li Y, Yang J, Yang C, et al. FTH promotes the proliferation and renders the HCC cells specifically resist to ferroptosis by maintaining iron homeostasis. Cancer Cell Int 2021, 21(1): 709.
8. Li Y, Xu B, Ren X, Wang L, Xu Y, Zhao Y, et al. Inhibition of CISD2 promotes ferroptosis through ferritinophagy-mediated ferritin turnover and regulation of p62-Keap1-NRF2 pathway. Cell Mol Biol Lett 2022, 27(1): 81.
9. Du J, Huang Z, Li Y, et al. Copper exerts cytotoxicity through inhibition of iron-sulfur cluster biogenesis on ISCA1/ISCA2/ISCU assembly proteins. Free Radic Biol Med. 2023;204:359-373. (number of citations: 2)
10. Lei G, Tang L, Yu Y, Bian W, Yu L, Zhou J, et al. The potential of targeting cuproptosis in the treatment of kidney renal clear cell carcinoma. Biomed Pharmacother 2023, 167: 115522.
11. Yang L, Wu Y, Jin W, Mo N, Ye G, Su Z, et al. The potential role of ferroptosis in COVID-19-related cardiovascular injury. Biomed Pharmacother 2023, 168: 115637.
12. Wu Y, Li Y, Gao Y, Zhang P, Jing Q, Zhang Y, et al. Immunotherapies of acute myeloid leukemia: Rationale, clinical evidence and perspective. Biomed Pharmacother 2024, 171: 116132.
13. Zhang P, Zhou C, Ren X, Jing Q, Gao Y, Yang C, et al. Inhibiting the compensatory elevation of xCT collaborates with disulfiram/copper-induced GSH consumption for cascade ferroptosis and cuproptosis. Redox Biol. 2024, 69: 103007.
14. Du J, Yu L, Yang X, et al. Regulation of NCOA4-mediated iron recycling ameliorates paraquat-induced lung injury by inhibiting ferroptosis. Cell Communication and Signaling. 2024, DOI : 10.1186/s12964-024-01520-1.
目前参与二十余名硕士研究生的带教,参与博士生带教二名。